Archives: Speakers

Johanna Morand is the Associate Director, Site Contracts, at Premier Research, responsible for EMEA, LATAM, and APAC, along with the Benelux Country Lead. She has 12 years of experience negotiating contracts for clinical trials (previously with Genzyme, a Sanofi Company, Parexel, and Cmed). Ms. Morand leads an international team of Contract Leads and Contract Specialists. Her aim remains to balance timely execution while managing legal, financial, and operational risks. Ms. Morand holds an LLM in European Law from Leiden University and an LLM in Law and Economics from Utrecht University where she wrote a thesis on European Orphan Medicinal Product Regulations.

Dr. Mahillo has 28+ years of experience in the clinical research arena, 25 of them in oncology global trials. Her areas of expertise are inmuno-oncology, including cancer vaccines, advanced therapies, genetically modified organisms and other immuno therapies. She has an in-depth knowledge on oncology networks and advocacy groups, with which she cooperates since 1999. Dr. Mahillo is a professor/magister in several Master programs administered at different Universities (Universidad Alcalá de Henares, Universidad CEU San Pablo, CESIF). She has authored of 3 books, 20 scientific articles, and 24 contributions to scientific congresses. Dr. Mahillo was awarded the first prize of the Spanish Society of Medical Oncology (SEOM) in 2015 for her project “Y Seguiré” (will keep on moving), for the promotion of clinical research. Dr. Mahillo obtained her PhD with a research on the role of multicatalytic proteinase (proteasome) as an oncology intracellular target, research line that ended up with the development of bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma patients.

After qualifying as a barrister, Ian re-trained as a chartered accountant with Deloitte, working with brokers and insurers in the UK and international markets.  Over 14 years, he helped build a regulatory consulting practice of 50 professionals, led the client money and regulatory diligence offering for Deloitte, conducted skilled persons investigations and supported insurance clients on all aspects of UK financial regulation.  In 2020, Ian joined Aston Lark Group as Chief Risk Officer, working alongside Peter Blanc to transform the governance, risk and compliance arrangements and supporting the business through more than 30 acquisitions.  Ian is responsible for the ESG strategy for the Aston Lark Group, expanding its remit as the group has grown by adding new initiatives and networks and increasing staff engagement.

Ignacio joined Janssen in 2014 as part of the GOLD Program.  He completed 3 international rotations as a Drug Product Demand Planner, Process Engineer, and SAP Master Data Team Lead.  Subsequently Ignacio became the JIT (Just-in-Time) Team Lead while working as a Staff Engineer Tech. Development & Innovation. Driven by curiosity and willingness to help others, Ignacio relocated to Nigeria for 6 months to work for a Maternal and Newborn Health NGO under J&J’s Secondment Program. Shortly after his return, Ignacio joined the CAR-T Systems Group to help deploy end-to-end tools for new emerging modalities within the Biotherapeutics Clinical Supply Chain.

As Vice President of Marketing and Partnerships, Libbi drives enterprise growth through data-driven strategy, integrated marketing leadership, and high-value alliance development. She combines deep expertise in e-clinical innovation and life sciences with a collaborative, cross-functional approach to guide strategic decisions, cultivate impactful partnerships, and translate market insights into measurable outcomes.

Markus is the CEO of LIKE MAGIC (likemagic.tech), bringing strong leadership capabilities and deep expertise in innovation, business transformation, and change management across the financial services (banking and credit cards) and hospitality sectors. He has a proven track record of identifying, designing, and implementing user-centric innovations—both within corporate environments and in collaboration with startups—that deliver measurable impact on business performance and drive sustainable growth.

He continues to demonstrate this skill in his current role as CEO of LIKE MAGIC—a company he successfully built from the ground up and spun out as a subsidiary of SV Group. LIKE MAGIC is now being adopted by an expanding portfolio of hotels and serviced apartment providers across Central and Western Europe, as well as Australia, including Schani Hotels, Stay KooooK, IBIS Styles Nagold, The Zipper Hotel (Hospitality X), McDreams Hotels, and others.

Based in the UK, Chris is responsible for global cell & gene therapy logistics. Since joining Biocair in 2002, Chris has demonstrated Biocair’ s unique client-centric approach by leading teams to deliver in a wide range of challenging situations. He helps meet the complex supply chain needs necessary for commercial distribution of FDA approved therapies